| Literature DB >> 31844425 |
Velmurugan Chinnasamy1, Vetriselvan Subramaniyan2, Sarath Chandiran3, Saminathan Kayarohanam4, Dhanapal Chidambaram Kanniyan5, Venkata Sathya Saiappala Raju Velaga6, Shafiulla Muhammad7.
Abstract
AIM: To determine the ameliorative potential of aqueous extract of Achyranthesaspera(AEAA) against arthritis using swiss albino mice and Wistar rats, and its possible mechanism of action.Entities:
Keywords: Achyranthesaspera; Anti-arthritis; Arthritis; Formaldehyde
Year: 2019 PMID: 31844425 PMCID: PMC6901860 DOI: 10.3889/oamjms.2019.559
Source DB: PubMed Journal: Open Access Maced J Med Sci ISSN: 1857-9655
Preliminary phytochemical screening of aqueous extract of Achyranthesaspera
| Sl. No | Constituents | Observation in AEAA |
|---|---|---|
| 1. | Alkaloids | Positive |
| 2. | Carbohydrates | Positive |
| 3. | Glycosides | Positive |
| 4. | Phenolic compounds | Positive |
| 5. | Flavonoids | Positive |
| 6. | Tannin and Proteins | Positive |
Figure 1Radiography of the rat joints in formaldehyde induced arthritic model; A) Normal Control (DMSO 2 ml/kg); B) Negative control; C) Standard (Diclofenac 10 mg/kg); D) AEAA 125 mg/kg; E) AEAA 250 mg/kg; F) AEAA 500 mg/kg
Figure 2Histological examination of experimental rats; A) Normal Control (DMSO 2 ml/kg); B) Negative control; C) Standard (Diclofenac 10 mg/kg); D) AEAA 125 mg/kg; E) AEAA 250 mg/kg; F) AEAA 500 mg/kg
Effect of aqueous extract of Achyranthesasperaon Hb, ESR & RA factor
| Groups | Treatment & Dose | Hb mg/dl | ESR mm/hr | RA factor |
|---|---|---|---|---|
| 1 | Normal Control | 16.8 + 0.35 | 11.9 + 0.54 | Negative |
| 2 | Negative Control | 9.58 + 1.04 | 23.25 + 1.49 | Positive |
| 3 | Diclofenac (10 mg/kg) | 14.56 + 0.81** | 8.96 + .42** | Negative |
| 4 | AEAA 125 mg/kg | 10.64 + 0.7ns | 24.32 + 0.31ns | Positive |
| 5 | AEAA 250 mg/kg | 12.86 + 0.42** | 7.73 + .28** | Negative |
| 6 | AEAA 500 mg/kg | 15.71 + 0.28** | 10.44 + 0.57** | Negative |
Effect of AEAA on joint swelling (Paw volume)
| Groups | Treatment & Dose | Paw volume in ml | % inhibition of paw volume on 21st day | ||||
|---|---|---|---|---|---|---|---|
| 1st day | 7th day | 14th day | 21st day | 28th day | |||
| 1 | Normal Control | 0.04 ± 0.00 | 0.04 ± 0.00 | 0.05 ± 0.00 | 0.05 ± 0.00 | 0.04 ± 0.00 | - |
| 2 | Negative Control | 0.26 ± 0.01 | 0.46 ± 0.01 | 0.55 ± 0.02 | 0.6 ± 0.02 | 0.67 ± 0.01 | 0 |
| 3 | Diclofenac (10 mg/kg) | 0.20 ± .02** | 0.31 ± 0.03** | 0.34 ± 0.01** | 0.38 ± 0.02** | 0.33 ± 0.01** | 36.6 |
| 4 | AEAA 125 mg/kg | 0.25 ± 0.02ns | 0.42 ± 0.02ns | 0.52 ± 0.02ns | 0.54 ± 0.02ns | 0.65 ± 0.01ns | 10 |
| 5 | AEAA 250 mg/kg | 0.21 ± 0.00** | 0.37 ± 0.01** | 0.38 ± 0.00** | 0.42 ± 0.02** | 0.38 ± 0.02** | 30 |
| 6 | AEAA 500 mg/kg | 0.18 ± 0.00** | 0.30 ± 0.02** | 0.35 ± 0.01** | 0.37 ± 0.01** | 0.31 ± 0.02** | 38.33 |
Effect of AEAA on the joint diameter
| Groups | Treatment & Dose | Joint diameter in mm | % inhibition of joint diameter 14th day | ||||
|---|---|---|---|---|---|---|---|
| 1st day | 7th day | 14th day | 21st day | 28th day | |||
| 1 | Normal Control | 0.42 ± 0.02 | 0.42 ± 0.02 | 0.42 ± 0.02 | 0.42 ± 0.01 | 0.43 ± 0.01 | - |
| 2 | Negative Control | 0.55 ± 0.02 | 0.69 ± 0.01 | 0.77 ± 0.01 | 0.81 ± 0.02 | 0.89 ± 0.02 | 0 |
| 3 | Diclofenac (10 mg/kg) | 0.40 ± 0.03 | 0.42 ± 0.02 | 0.51 ± 0.03 | 0.47 ± 0.02 | 0.45 ± 0.02 | 36.61 |
| 4 | AEAA 125 mg/kg | 0.58 ± 0.02 | 0.66 ± 0.02 | 0.74 ± 0.01 | 0.78 ± 0.02 | 0.86 ± 0.01 | 3.89 |
| 5 | AEAA 250 mg/kg | 0.46 ± 0.01 | 0.48 ± 0.01 | 0.56 ± 0.01 | 0.55 ± 0.03 | 0.50 ± 0.03 | 27.2 |
| 6 | AEAA 500 mg/kg | 0.38 ± 0.01 | 0.42 ± 0.02 | 0.49 ± 0.02 | 0.45 ± 0.02 | 0.45 ± 0.02 | 36.36 |